About
Dr. Larry Lasky is an expert in biotechnology, a field that he has worked in commercially for over 32 years. In 1981, he was the founding scientist of Genetics Institute (acquired by Wyeth), one of the earliest biotechnology companies. Subsequently he was a leading scientist at Genentech for 20 years where he attained the company's highest scientific position, Genentech Fellow, before he retired in 2002 (there have been 3 Genentech Research Fellows in the Company's history). Dr. Lasky joined USVP in 2007 and was the founding investor of Cleave Biosciences and led the firm's participation in Intellikine and Calithera Biosciences. As a General Partner and co-founder of Latterell Venture Partners from 2002 to 2007, Dr. Lasky was the founding investor of Proteolix (acquired by Onyx Pharmaceuticals) and OncoMed Pharmaceuticals and was instrumental in the founding of Cellective Therapeutics (acquired by Medimmune), Tetralogic, and BioVerdant. "We are living in an extraordinary era of discove
Position in the VCSift Database
- • 8 investors at The Column Group are tracked.
- • 1,303 investors hold the Partner role in VCSift. Larry Lasky is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like Larry
Search Investors